Investment
In December 2018, Spineart group made a major investment in Pytheas, a start-up based in Marseille, France, specialized in spine surgery planification and navigation.
Thanks to this investment, Spineart is poised to maintain its place at the forefront of innovation on the dynamic Spine market.
Sales Record
In March, Spineart USA revenues reached a new record by exceeding for the first time the symbolic $2.5 millions mark; during this month a record 375 US patients were treated with Spineart implants.
Overall, very good sales performances worldwide in Q1 2019 with an outstanding growth in the US of +34,9% versus Q1 2018, +14,7% in EU direct and +8,1% Rest Of the World.
Congratulations to the US team, to the sales team worldwide and to the “shadow workers” who serve and support them on a daily basis and allow them to focus on expanding Spineart’s footprint in the spine market.
1st surgery SCARLET® AL-T
Spineart is proud to announce the release of its secured anterior lumbar cage, SCARLET® AL-T.
SCARLET® AL-T is a stand-alone, zero profile Anterior Lumbar Interbody Cage featuring our Ti-LIFE technology enhanced algorithm for additive manufacturing resulting in a porous structure that mimics trabecular bone.
The first surgery was reported on Dec 12th, 2018 in the US.
Sales Records Q4
Spineart USA Inc. reported $23.1M in revenue for the calendar year 2018, an increase of 20% vs 2017. During the fourth quarter of the year, Spineart USA Inc. achieved a record month revenue in November with $2.4M.
Also, Revenues OUS reported a record quarter in Q4 with over 9m€ of invoicing.
Spineart in the Capital magazine
Eurospine/NASS
Spineart attended Eurospine Congressheld in Barcelona on Sept. 19 to 21, 2018 as Silver Partner and NASS Congress (North American Spine Society) held in Los Angeles from Sept. 26 to 29, 2018. Those two major events allowed us to demonstrate, in our booth, our latest technologies to Physicians coming from all over the world and to conduct numerous business and R&D meetings with KOL's and distributors.